Увійти

Готові списки джерел за темами / Cancer Radiotherapy

Добірка наукової літератури з теми "Cancer Radiotherapy"

Автор: Grafiati

Опубліковано: 4 червня 2021

Оновлено: 6 вересня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Cancer Radiotherapy".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Зміст

Статті в журналах
Дисертації
Книги
Частини книг
Тези доповідей конференцій
Звіти організацій

Статті в журналах з теми "Cancer Radiotherapy":

1

Sukarno, Vania, I. Widyadharma, Ida Wijayanti, Kumara Tini, and Ngakan Ganapati. "Pain Characteristics of Cervical Cancer Patient Who Underwent Radiotherapy in Bali, Indonesia." International Journal of Medical Reviews and Case Reports 4, Reports in Microbiology, Infecti (2020): 1. http://dx.doi.org/10.5455/ijmrcr.cervical-cancer-radiotherapy-bali.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Mohamed Traore, Wend-Yam, Behyamet Onka, Ibrahima Dokal Diallo, Rachida Latib, and Youssef Omor. "Post-radiotherapy recto-vaginal fistula in cervical cancer." International Journal of Case Reports and Images 13, no. 2 (October 3, 2022): 153–55. http://dx.doi.org/10.5348/101349z01wt2022ci.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Lee, B.-J., S.-G. Wang, H.-J. Roh, E.-K. Goh, K.-M. Chon, and D.-Y. Park. "Changes in expression of p53, proliferating cell nuclear antigen and bcl-2 in recurrent laryngeal cancer after radiotherapy." Journal of Laryngology & Otology 120, no. 7 (May 4, 2006): 579–82. http://dx.doi.org/10.1017/s0022215106001150.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The biological changes in recurrent laryngeal cancer following radiotherapy are not fully understood. The authors investigated differences in the expression of p53, proliferating cell nuclear antigen (PCNA) and bcl-2 in laryngeal cancer specimens before radiotherapy and in recurrent laryngeal cancer specimens following radiotherapy in the same patients. The authors investigated the expression of p53, PCNA and bcl-2 by immunohistochemical stain in 30 specimens from 15 patients with primary laryngeal cancer and recurrent laryngeal cancer after radiotherapy.The expression of p53 protein was significantly different in laryngeal cancer before radiotherapy (4/15, 26.7 per cent) compared with recurrent laryngeal cancer after radiotherapy (8/15, 53.3 per cent) (p < 0.05). The PCNA index was also significantly different in laryngeal cancer specimens before radiotherapy (mean, 11.9 per cent) compared with recurrent laryngeal cancer after radiotherapy (mean, 18.0 per cent) (p < 0.05). However, there was no statistically significant alteration of bcl-2 expression in primary compared with recurrent laryngeal cancer. The expression of p53 and PCNA increased in recurrent laryngeal cancers after radiotherapy, compared with that in laryngeal cancers before radiotherapy. Recurrent laryngeal cancers arising following radiotherapy became biologically aggressive.

4

Manzoor, Najmi Arshad. "Unplanned Interruption of Radiotherapy in Head and Neck Cancers: report from a Regional Cancer Centre." Journal of Medical Science And clinical Research 05, no. 04 (April 14, 2017): 20294–300. http://dx.doi.org/10.18535/jmscr/v5i4.90.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Stepanović, Aleksandar, Tatjana Arsenijevic, Vesna Stankovic, Vukac Vujanac, Anja Lazovic, Tanja Raonic-Stevanovic, and Marina Nikitovic. "Clinical analysis of COVID-19 positive cancer inpatients in National Cancer Center in Serbia." Journal of Infection in Developing Countries 15, no. 09 (September 30, 2021): 1286–92. http://dx.doi.org/10.3855/jidc.15104.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Introduction: The outbreak of COVID-19 has had an impact on global healthcare as well as on radiotherapy practice in many countries. This study aimed to identify clinical characteristics of Coronavirus Disease 2019 (COVID-19) infected cancer inpatients, as well as what impact this infection had on radiation treatment of the patients. Methodology: In this retrospective study, we included cancer inpatients with laboratory confirmed COVID-19 infection during the radiotherapy or chemoradiation in April 2020 in National Cancer Research Center in Serbia. Data were obtained from the medical records between 1 April and 1 July 2020. Results: A total of 49 COVID-19 infected cancer inpatients were included. The most frequently reported cancers were head and neck cancers, in twenty-three patients (46.8%). Lymphopenia was present in 77.5% of the patients. Red blood cells, haemoglobin and platelets were significantly lower during incubation or diagnosis of COVID-19. Twenty-seven (55.1%) patients did not finish radiotherapy. The age of patients who finished radiotherapy after COVID-19 infection was significantly lower compared to the patients who did not finish radiotherapy (60.5 ± 7.8 vs. 68.6 ± 11.2; p < 0.005). Conclusions: COVID-19 infected cancer patients in radiotherapy practice show similar symptoms and demographic characteristics as the general population infected with SARS-CoV-2 virus. Patients with head and neck cancers may be susceptible to infection with COVID-19. Old age and male gender may be risk factors for discontinuation of radiotherapy in COVID-19 infected cancer patients.

6

Hsieh, Kristin, Daniel R. Dickstein, Juliana Runnels, Eric J. Lehrer, Kenneth Rosenzweig, Fred R. Hirsch, and Robert M. Samstein. "Radiotherapy and Immunotherapy in Lung Cancer." Biomedicines 11, no. 6 (June 6, 2023): 1642. http://dx.doi.org/10.3390/biomedicines11061642.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The emergence of immune checkpoint inhibitors (ICIs) as a pillar of cancer treatment has emphasized the immune system’s integral role in tumor control and progression through cancer immune surveillance. ICIs are being investigated and incorporated into the treatment paradigm for lung cancers across stages and histology. To date, definitive concurrent chemoradiotherapy followed by consolidative durvalumab is the only National Comprehensive Cancer Network’s recommended treatment paradigm including radiotherapy with ICI in lung cancers, although there are other recommendations for ICI with chemotherapy and/or surgery. This narrative review provides an overall view of the evolving integration and synergistic role of immunotherapy and radiotherapy and outlines the use of immunotherapy with radiotherapy for the management of small cell lung cancer and non-small cell lung cancer. It also reviews selected, practice-changing clinical trials that led to the current standard of care for lung cancers.

7

Chandra, Ade, Sukri Rahman, Al Hafiz, Eva Decroli, and Hafni Bachtiar. "Pengaruh Radioterapi Terhadap Kadar TSH dan T4 pada Pasien Tumor Ganas Kepala dan Leher." Oto Rhino Laryngologica Indonesiana 48, no. 2 (January 30, 2019): 159. http://dx.doi.org/10.32637/orli.v48i2.238.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Latar belakang: Tumor ganas kepala dan leher adalah tumor ganas yang berasal dari epitel traktus aerodigestif atas. Radioterapi adalah salah satu modalitas talaksana pada tumor ganas kepala dan leher. Kelenjar tiroid akan terpapar radioterapi selanjutnya merangsang terjadinya kelainan pada kelenjar tiroid. Hipotiroid merupakan efek samping yang paling umum terjadi akibat radioterapi. Diagnosis hipotiroid ditegakkan melalui pemeriksaan laboratorium yaitu didapatkan peningkatan TSH dan penurunan T4. Tujuan: Mengetahui pengaruh radioterapi terhadap kadar TSH dan T4 pasien tumor ganas kepala dan leher di RSUP Dr. M. Djamil, Padang. Metode: Analitik cross sectional dengan desian pre and post test only pada 10 responden tumor ganas kepala dan leher. Sampel berupa darah vena yang dihitung kadar TSH dan T4 menggunakan alat Vidas 3. Data dianalisis dengan uji t berpasangan. Hasil analisis statistik dinyatakan bermakna bila didapatkan hasil p<0,05. Hasil: Nilai rerata kadar TSH sebelum dan setelah radioterapi didapatkan 0,57 ± 0,512 µIU/ml. Nilai rerata kadar T4 sebelum dan setelah radioterapi didapatkan 0,721 ± 0,508 µg/dL. Uji t bepasangan didapatkan peningkatan rerata kadar TSH setelah radioterapi dengan p = 0,004 yang menunjukkan peningkatan bermakna rerata kadar TSH setelah radioterapi dan didapatkan penurunan rerata kadar T4 setelah radioterapi dengan p = 0,001 yang menunjukkan penurunan bermakna rerata kadar T4 setelah radioterapi. Kesimpulan: Terdapat peningkatan bermakna rerata kadar TSH serta penurunan rerata kadar T4 sebelum dan setelah radioterapi pada pasien tumor ganas kepala dan leher walau belum melewati nilai normal.ABSTARCTBackground: Head and neck cancers are malignancies that originate from upper aerodigestive tract epithelium. Radiotherapy is one of the modalities treatments for head and neck cancer. Thyroid glands which exposed by radiotherapy, furthermore can induce abnormalities. Hypothyroid is a most common abnormality that occur after radiotherapy. Diagnosis hypothyroidism can be established through laboratory examination that is obtained an increased levels of TSH and decreased levels of T4. Purpose: To determine effect radiotherapy on levels of TSH and T4 in patients with head and neck cancer in Dr. M. Djamil Hospital, Padang. Methods: Cross sectional analytic study with pre and post test only on 10 respondents with head and neck cancer. Samples taken from venous blood then TSH and T4 were counted with Vidas 3. Data was analyzed with paired t-test. The statistical result was significant with p<0,05. Result: Mean value of TSH before and after radiotherapy is 0,57 ± 0,512 µUI/ml. Mean value of T4 before and after radiotherapy is 0,721 ± 0,508 µg/dL. From paired t-test resulted an increase of TSH mean value after radiotheraphy with p = 0,004 which implies a significant enhancement of TSH mean value after radiotheraphy and decreasing T4 mean value after radiotheraphy with p = 0,001 which implies a significant deflation of T4 mean value after radiotheraphy. Conclusions: There was significant enhancement of TSH mean and significant deflation of T4 mean value before and after radiotherapy on patients with head and neck cancer even still within normal value. Keywords: Radiotheraphy, TSH, T4, head and neck cancer.

8

Shirai, Katsuyuki, Akiko Nakagawa, Takanori Abe, Masahiro Kawahara, Jun-ichi Saitoh, Tatsuya Ohno, and Takashi Nakano. "Use of FDG-PET in Radiation Treatment Planning for Thoracic Cancers." International Journal of Molecular Imaging 2012 (May 14, 2012): 1–9. http://dx.doi.org/10.1155/2012/609545.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Radiotherapy plays an important role in the treatment for thoracic cancers. Accurate diagnosis is essential to correctly perform curative radiotherapy. Tumor delineation is also important to prevent geographic misses in radiotherapy planning. Currently, planning is based on computed tomography (CT) imaging when radiation oncologists manually contour the tumor, and this practice often induces interobserver variability. F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has been reported to enable accurate staging and detect tumor extension in several thoracic cancers, such as lung cancer and esophageal cancer. FDG-PET imaging has many potential advantages in radiotherapy planning for these cancers, because it can add biological information to conventional anatomical images and decrease the inter-observer variability. FDG-PET improves radiotherapy volume and enables dose escalation without causing severe side effects, especially in lung cancer patients. The main advantage of FDG-PET for esophageal cancer patients is the detection of unrecognized lymph node or distal metastases. However, automatic delineation by FDG-PET is still controversial in these tumors, despite the initial expectations. We will review the role of FDG-PET in radiotherapy for thoracic cancers, including lung cancer and esophageal cancer.

9

Vendrely, V., E. Rivin Del Campo, A. Modesto, M. Jolnerowski, N. Meillan, S. Chiavassa, A. A. Serre, et al. "Rectal cancer radiotherapy." Cancer/Radiothérapie 26, no. 1-2 (February 2022): 272–78. http://dx.doi.org/10.1016/j.canrad.2021.11.002.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

NISHIO, MASAMICHI. "Radiotherapy for Cancer." Journal of the Atomic Energy Society of Japan / Atomic Energy Society of Japan 37, no. 6 (1995): 482–87. http://dx.doi.org/10.3327/jaesj.37.482.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "Cancer Radiotherapy":

1

Mairs, Robert J. "Targeted radiotherapy of cancer." Thesis, University of Glasgow, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.248190.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Radu, Calin. "Optimising Radiotherapy in Rectal Cancer Patients." Doctoral thesis, Uppsala universitet, Enheten för onkologi, 2012. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-172531.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Rectal cancer is the eight most common cancer diagnosis in Sweden in both men and women, with almost 2000 new cases per year. Radiotherapy, which is an important treatment modality for rectal cancer, has evolved during the past decades. Diagnostic tools have also improved, allowing better staging and offering information used to make well-founded decisions in multidisciplinary team conferences. In a retrospective study (n=46) with locally advanced rectal cancer (LARC) patients, unfit for chemoradiotherapy, patients were treated with short-course radiotherapy. Delayed surgery was done when possible. Radical surgery was possible in 89% of the patients who underwent surgery (80%). Grade IV diarrhoea affected three elderly patients. Target radiation volume should be reduced in elderly or metastatic patients. In a prospective study (n=68) with LARC patients, magnetic resonance imaging (MRI) and 2-18F-fluoro-2-D-deoxyglucose (FDG) positron emission tomography (PET) were used to determine if FDG-PET could provide extra treatment information. Information from FDG-PET changed the stage of 10 patients. Delineation with FDG-PET generally resulted in smaller target volumes than MRI only. Seven of the most advanced LARC patients in the above cohort were used for a methodological study to determine if dose escalation to peripheral, non-resectable regions was feasible. Simultaneous integrated boost plans with photons and protons were evaluated. While toxicity was acceptable in five patients with both protons and photons, two patients with very large tumours had unacceptable risk for intestinal toxicity regardless of modality. In the interim analysis of the Stockholm III Trial (n=303, studying radiotherapy-fractionation and timing of surgery in relation to radiotherapy) compliance was acceptable and severe acute toxicity was infrequent, irrespective of fractionation. Short-course radiotherapy with immediate surgery tended to give more postoperative complications, but only if surgery was delayed more than 10 days after the start of radiotherapy. Quality-of-life in the Stockholm III Trial was studied before, during and shortly after treatment using the EORTC QLQ-C30 and CR38 questionnaires. Surgery accounted for more adverse effects than radiotherapy in all groups. Postoperatively, the poorest quality-of-life was seen in patients given short-course radiotherapy followed by immediate surgery. No postoperative differences were seen between the two groups with delayed surgery.

3

Martling, Anna. "Rectal cancer : staging, radiotherapy and surgery /." Stockholm, 2003. http://diss.kib.ki.se/2003/91-7349-461-5/.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Langlands, Fiona Elizabeth. "Sensitivity to radiotherapy in breast cancer." Thesis, University of Leeds, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.582111.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Radiotherapy (RT) is a component of treatment for breast cancer in more than 50% of cases. Patients are selected for RT on the basis of limited clinical and histopathological factors with no reference to the molecular phenotype of tumours. Breast cancer is a highly heterogeneous disease and some tumours are refractory to RT treatment. Selection of patients for RT using predictive markers may improve RT efficacy and cancer outcomes. The aims of the work described in this thesis were to identify and test potential predictive markers for RT in cancer treatment. I examined whether the classic histopathological breast cancer subtypes or the levels of expression of five molecular markers, 26S proteasome, GRP78, HJURP, IGFlR and PARPl, would provide predictive insights into response to RT in the context of both cultured breast cancer cell lines, and archival patient samples supported by clinical follow up. Clonogenic survival assays revealed that cell lines representative of luminal or basal breast cancers did not display subtype specific responses to RT. Similarly, expression levels of 26S proteasome, GRP78, HJURP, IGFlR and PARPl did. not correlate with specific responses to RT in cell lines. In breast cancer patients who underwent RT high expression of 26S proteasome was significantly associated with increased rates of local recurrence. High expression of HJURP was associated with reduced rates of local recurrence, as was high expression of PARPl. Importantly, these associations were not found in patients who were treated without RT, suggesting that these markers provide predictive in sights into RT response, rather than prognostic insights into the likelihood of local recurrence overall. Finally, high expression of 26S proteasome was also found to be associated with increased rates of local recurrence in bladder cancer patients, suggesting that this marker may have predictive value for RT in a range of cancer settings.

5

Taylor, Carolyn W. "Breast cancer radiotherapy and heart disease." Thesis, University of Oxford, 2008. http://ora.ox.ac.uk/objects/uuid:c9dda3ca-8cb3-4a38-938d-0b75b4f6471d.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Introduction: Some past breast cancer radiotherapy regimens led to an increased risk of death from heart disease. Although heart dose from breast cancer radiotherapy has generally reduced over the past few decades, there may still be some cardiac risk. Estimation of future risk for women irradiated today requires both measurement of their cardiac dose and dose-response relationships, which depend on cardiac dosimetry of past regimens, in conjunction with long-term follow-up data. Methods: Virtual simulation and computed tomography 3-dimensional treatment planning on a representative patient were used to estimate mean heart and coronary artery doses for women irradiated since 1950 in 71 randomised trials in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) overview. Patient-to-patient variability in cardiac dose was assessed. Heart and coronary artery doses were also calculated for breast cancer radiotherapy regimens used since the 1950s in Sweden. Cardiac doses from contemporary (year 2006) radiotherapy were assessed for 55 patients who received tangential breast cancer irradiation at a large UK radiotherapy centre. The maximum heart distance (i.e. the maximum distance between the anterior cardiac contour and the posterior tangential field edges) was measured for the left-sided patients, and its value as a predictor of cardiac doses assessed. Results: Mean heart dose for women irradiated in the EBCTCG trials varied from <1 to 18 Gray, and mean coronary artery dose from <1 to 57 Gray. Patient-to-patient variability was moderate. Mean heart dose for women irradiated in Sweden since the 1950s varied from <1 to 24 Gray, and mean coronary artery dose from <1 to 46 Gray. Heart dose from tangential irradiation has reduced over the past four decades. However, mean heart dose for left-sided patients irradiated in 2006 was 2 Gray and around half of them still received >20 Gray to parts of the heart and left anterior descending coronary artery. For these patients, maximum heart distance was a reliable predictor of cardiac doses. For the other patients, mean heart dose varied little and was usually less than 2 Gray. Conclusions: Cardiac doses from breast cancer radiotherapy can be estimated reliably and are now available for use in deriving dose-response relationships in the EBCTCG data and in a Scandinavian case-control study. Cardiac dose has reduced over the past four decades. Therefore the cardiac risk is also likely to have reduced. Nevertheless, for some patients, parts of the heart still receive >20 Gray in the year 2006.

6

吳曉靑 and Xiaoqing Wu. "Post-radiotherapy cervical metastasis in nasopharyngeal carcinoma." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 1999. http://hub.hku.hk/bib/B31222018.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Cheng, Kun. "Deformable models for adaptive radiotherapy planning." Thesis, University of Edinburgh, 2016. http://hdl.handle.net/1842/22893.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Radiotherapy is the most widely used treatment for cancer, with 4 out of 10 cancer patients receiving radiotherapy as part of their treatment. The delineation of gross tumour volume (GTV) is crucial in the treatment of radiotherapy. An automatic contouring system would be beneficial in radiotherapy planning in order to generate objective, accurate and reproducible GTV contours. Image guided radiotherapy (IGRT) acquires patient images just before treatment delivery to allow any necessary positional correction. Consequently, real-time contouring system provides an opportunity to adopt radiotherapy on the treatment day. In this thesis, freely deformable models (FDM) and shape constrained deformable models (SCDMs) were used to automatically delineate the GTV for brain cancer and prostate cancer. Level set method (LSM) is a typical FDM which was used to contour glioma on brain MRI. A series of low level image segmentation methodologies are cascaded to form a case-wise fully automatic initialisation pipeline for the level set function. Dice similarity coefficients (DSCs) were used to evaluate the contours. Results shown a good agreement between clinical contours and LSM contours, in 93% of cases the DSCs was found to be between 60% and 80%. The second significant contribution is a novel development to the active shape model (ASM), a profile feature was selected from pre-computed texture features by minimising the Mahalanobis distance (MD) to obtain the most distinct feature for each landmark, instead of conventional image intensity. A new group-wise registration scheme was applied to solve the correspondence definition within the training data. This ASM model was used to delineated prostate GTV on CT. DSCs for this case was found between 0.75 and 0.91 with the mean DSC 0.81. The last contribution is a fully automatic active appearance model (AAM) which captures image appearance near the GTV boundary. The image appearance of inner GTV was discarded to spare the potential disruption caused by brachytherapy seeds or gold markers. This model outperforms conventional AAM at the prostate base and apex region by involving surround organs. The overall mean DSC for this case is 0.85.

8

Taylor, Alexandra. "Intensity-modulated radiotherapy for cervical cancer : optimising target volume definition and radiotherapy delivery." Thesis, University of London, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.510901.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Murphy, Caroline Claire Scanlon. "A history of radiotherapy to 1950 : cancer and radiotherapy in Britain 1850-1950." Thesis, University of Manchester, 1986. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.278710.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Riekki, R. (Riitta). "Late dermal effects of breast cancer radiotherapy." Doctoral thesis, University of Oulu, 2006. http://urn.fi/urn:isbn:9514282760.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Abstract Radiotherapy is used in the treatment of breast cancer in order to reduce local recurrence rate. However, radiation is known to cause both acute and delayed side-effects on normal tissues. A common late complication of radiotherapy is fibrosis of skin and other organs. Fibrosis has been described as excessive accumulation of extracellular matrix components, especially collagens. Collagens are a group of extracellular matrix proteins that provide connective tissues with tensile strength. Type I and III collagens are the major structural proteins in skin. Alterations in collagen synthesis occur in various pathological conditions, during ageing and in association with diverse medical therapies. Collagens are degraded by matrix metalloproteinase enzymes (MMPs). The activity of MMPs is restrained by their specific tissue inhibitors (TIMPs). Elastic fibres constitute about 2–4% of skin dry weight. Despite their low quantity, elastic fibres are responsible for the resilient and elastic properties of skin. Dermal elastic fibres may be affected by intrinsic ageing, by extrinsic reasons such as photodamage and in several connective tissue diseases. The effect of radiotherapy on human skin type I and III collagen synthesis was investigated in a group of women who had been treated for breast cancer surgically and with radiotherapy. The levels of MMP-9, MMP-2/TIMP-2 complex, TIMP-1 and TIMP-2 in irradiated skin were also analysed. The effect of radiotherapy on elastic fibres was analysed using skin samples. The physio-mechanical properties of radiotherapy-treated skin were studied using ultrasound and elastometer devices, and compared with those of non-treated skin. In addition, skin samples were stained for haematoxylin-eosin, tenascin and mast cells. Factor VIII immunostaining was performed to visualize dermal blood vessels. Wound regeneration in irradiated skin was also studied using suction blister as a model. The synthesis of type I and III collagens was markedly increased as a result of radiotherapy. An increased amount of cross-linked type I collagen was detected in irradiated skin, and collagen turnover was also increased in irradiated skin. No difference in the amount or structure of the elastic fibres could be found between radiotherapy-treated and non-treated skin. A slight increase of skin thickness and stiffness was found in irradiated skin compared to non-treated skin. Increased tenascin expression was found in irradiated skin. The number of dermal blood vessels visualized by FVIII immunostaining was slightly higher in irradiated than in control skin. The amount of mast cells positive for tryptase, Kit receptor and chymase was increased in the upper dermis of irradiated skin. No difference in epidermal regeneration was found between irradiated and non-treated skin. The results of this study suggest that alteration of collagen metabolism contributes to dermal side effects of therapeutic irradiation.

Більше джерел

Книги з теми "Cancer Radiotherapy":

1

Seong, Jinsil, ed. Radiotherapy of Liver Cancer. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-16-1815-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Geinitz, Hans, Mack Roach III, and Nicholas van As, eds. Radiotherapy in Prostate Cancer. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-37099-1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Carlo, Greco, and Zelefsky Michael, eds. Radiotherapy of prostate cancer. Australia: Harwood Academic, 2000.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

International Cancer Research Data Bank., ed. Intraoperative radiotherapy. Bethesda, MD (Bldg. 82, Rm. 103, Bethesda 20892): U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, International Cancer Research Data Bank, 1988.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Rich, Tyvin A. Intraoperative radiotherapy. Bethesda, MD (Bldg. 82, Rm. 103, Bethesda 20892): U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, International Cancer Research Data Bank, 1988.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

C, Wang C., ed. Clinical radiation oncology: Indications, techniques, and results. Littleton, Mass: PSG Pub. Co., 1988.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Sara, Faithfull, and Wells Mary MSc, eds. Supportive care in radiotherapy. New York: Churchill Livingstone, 2003.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Priestman, Terry J. Coping with radiotherapy. London: Sheldon Press, 2007.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

B, Mittal Bharat, Purdy James A, and Ang K. K, eds. Advances in radiation therapy. Boston: Kluwer Academic Publishers, 1998.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Marcu, Loredana, Eva Bezak, and Barry Allen. Biomedical Physics in Radiotherapy for Cancer. London: Springer London, 2012. http://dx.doi.org/10.1007/978-0-85729-733-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Частини книг з теми "Cancer Radiotherapy":

1

Parker, Kate, Ann Maloney, and Debbie Wyatt. "Radiotherapy." In Cancer and Cancer Care, 194–216. 1 Oliver’s Yard, 55 City Road London EC1Y 1SP: SAGE Publications Ltd, 2015. http://dx.doi.org/10.4135/9781473920620.n13.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Veronesi, Umberto. "Radiotherapy." In Breast Cancer, 46–49. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-76054-9_7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Takayama, Kanako, Yusuke Demizu, and Nobukazu Fuwa. "Radiotherapy." In Oral Cancer, 285–306. Tokyo: Springer Japan, 2015. http://dx.doi.org/10.1007/978-4-431-54938-3_11.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Cozma, Adrian, Maitry Patel, Edward Chow, and Srinivas Raman. "Cancer: Radiotherapy." In Textbook of Palliative Medicine and Supportive Care, 623–38. 3rd ed. Boca Raton: CRC Press, 2021. http://dx.doi.org/10.1201/9780429275524-65.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Calvo, Felipe A., Oscar Abuchaibe, Javier Aristu, Javier Zudiare, and José María Berián. "Bladder Cancer." In Intraoperative Radiotherapy, 73–78. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-84183-5_10.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Calvo, Felipe A., David Ortiz de Urbina, Fernando de la Fuente, Matias Jurado, and José María Berián. "Gynecologic Cancer." In Intraoperative Radiotherapy, 79–84. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-84183-5_11.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Calvo, Felipe A., David Ortiz de Urbina, Jesús Herreros, and Rafael Llorens. "Lung Cancer." In Intraoperative Radiotherapy, 43–50. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-84183-5_6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Calvo, Felipe A., Manuel Santos, Fernando Pardo, José L. Hernández, Javier Alvarez-Cienfuegos, and Juan Voltas. "Gastric Cancer." In Intraoperative Radiotherapy, 51–56. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-84183-5_7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Calvo, Felipe A., Ignacio Azinovic, Gerardo Zornoza, Juan Voltas, Fernando Pardo, and Javier Alvarez-Cienfuegos. "Pancreatic Cancer." In Intraoperative Radiotherapy, 57–64. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-84183-5_8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Calvo, Felipe A., Ignacio Azinovic, Fernando Pardo, José L. Hernández, and Javier Alvarez-Cienfuegos. "Colorectal Cancer." In Intraoperative Radiotherapy, 65–72. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-84183-5_9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Cancer Radiotherapy":

1

Mason, Suzie, Yiannis Roussakis, Rongxiao Zhang, Geoff Heyes, Gareth Webster, Stuart Green, Brian Pogue, and Hamid Dehghani. "Cherenkov Radiation Portal Imaging during Photon Radiotherapy." In Cancer Imaging and Therapy. Washington, D.C.: OSA, 2016. http://dx.doi.org/10.1364/cancer.2016.jm3a.41.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Bax, Maria Luiza de Oliveira Almeida, Clécio Ênio Murta de Lucena, Calliny Cristina Pimentel Alves, and Matheus Assis dos Anjos Bastos Oliveira. "BREAST RECONSTRUCTION WITH AND WITHOUT ADJUVANT RADIOTHERAPY: A CRITICAL REVIEW." In Brazilian Breast Cancer Symposium 2022. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s2067.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Objective: Breast cancer is the most common malignancy in women worldwide. After mastectomy, many women wish to reconstruct the affected breast, and immediate breast reconstruction has proven to be oncologically safe in relation to just mastectomy. In addition, indications for post-mastectomy radiotherapy (PMRT) sessions are becoming more frequent, due to their relationship with reduced mortality and locoregional recurrence. For this reason, many women who opted for immediate reconstruction underwent radiotherapy with implants or expanders. This study aims to compare the outcomes of patients with breast cancer undergoing adjuvant radiotherapy after breast reconstruction surgery with an implant or expander with patients who did not need irradiation. Methods: A literature review was carried out on the CAPES Journal Portal. Results: The studies are unanimous when it comes to the increased risk of complications between the control groups and patients who have undergone PMRT. The reconstructive failure rates are lower, and the aesthetic results are better in surgeries with implants when compared with tissue expanders. Autologous surgeries are apparently safe and should be considered in the context of the PMRT. Conclusion: This review did not find sufficient scientific evidence to determine the best technique and the best period for radiotherapy in PMRT indications. It is concluded that the choice of the operative technique and the time of radiotherapy must be at the discretion of the surgeon and the multidisciplinary team of each service, always in a shared decision with the patient.

3

Demeshko, P. D., A. N. Batyan, and E. V. Hancharova. "METHODS FOR EVALUATING LONG-TERM RESULTS OF RADIOTHERAPY FOR CANCER WITH HIGH AND LOW PROLIFERATION POTENTIAL." In SAKHAROV READINGS 2021: ENVIRONMENTAL PROBLEMS OF THE XXI CENTURY. International Sakharov Environmental Institute, 2021. http://dx.doi.org/10.46646/sakh-2021-1-249-252.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The quality of radiation treatment for oncological diseases can be influenced by a large number of factors. Among them, the breaks that occur during the course of radiotherapy play an important role. Split courses of radiotherapy are used in the practice of radiation treatment of head and neck cancer, as well as prostate cancer. Breaks between the stages of the course of radiotherapy lasting 1-2 weeks are carried out in elderly, debilitated patients or in the presence of radiation reactions of 3-4 degrees. Before the start of radiotherapy, a set of measures is taken to prevent radiation reactions. This can affect the fact that the course of radiotherapy will be carried out without interruption. Using Cox regression, it is proposed to evaluate the effect of interruptions in the course of radiotherapy on the outcome of treatment for head and neck tumors, as well as the prostate tumors taking into account the observation period.

4

Meyer, Bianca dos Santos, Lélisa Pereira Oliveira, Carlos Antônio da Silva Franca, Reynaldo Real Martins Júnior, and Antônio Belmiro Rodrigues Campbell Penna. "IMPACT OF DELAYED ADJUVANT RADIOTHERAPY ON BREAST CANCER." In XXIV Congresso Brasileiro de Mastologia. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s1044.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Introduction: In documents from the Brazilian Society of Radiotherapy, quantitative analysis revealed that radiotherapy sessions, when performed, have not been timely. The average waiting time between the diagnosis data and the start of radiotherapy has been, on average, 113.4 days — which can consistently affect the chances of being cured for many patients. In some regions, waiting time is even longer; not infrequently, patients are treated with outdated methods and unprecision machines. Radiotherapy in Brazil is in a critical situation, especially with regard to the care of patients assisted by the Brazilian Public Health System (SUS). The main problems that contribute to this scenario are related to inadequate description and poor installation capacity, both from the point of view of the number of devices and their geographic distribution. Objective: The aim of this study was to determine whether delaying the initiation of adjuvant radiotherapy is related to decreased survival in women with breast cancer. Methods: This is a retrospective, descriptive, and longitudinal study (cross section) of patients admitted to the CRI/IBO, Niterói, RJ, all from SUS. Through the review of medical records, 81 patients were selected. Only patients diagnosed with stage IIb (T3N0) breast malignancy according to the American Joint Committee on Cancer TNM 8th (AJCC) were included. The analysis was performed by the time taken to start the radiotherapy after the initial treatment, which was treated by conservative surgery followed by adjuvant chemotherapy. The cohort was divided into two groups according to the timing of radiotherapy after the initial treatment: 6 months. Results: In the data analysis, it was observed that 70 (86.4%) patients did not have disease recurrence, while 11 (13.6%) patients had tumor recurrence. The average time between the end of the last chemotherapy day and the start of adjuvant radiotherapy was 6.1 months (1–12/95%CI 5.5–6.8, SD±2.9). Referring patients to those who provide adjuvant radiotherapy at 6 months (group B), we have 36 patients (44.4%) in group A and 45 patients (55.6%) in group B. In group A (36 patients), 34 patients (94.4%) did not have tumor recurrence and 2 (5.6%) did have tumor recurrence. In group B (45 patients), 36 (80%) patients did not have tumor recurrence and 9 (20%) did have tumor recurrence, with p=0.0001. Bearing in mind that the objective of the study is disease-free survival in 5 years, the mean follow-up time of patients was 69.8 months (51–92/95%CI 68.2–71.3, SD±7.0). It was evaluated that patients who had adjuvant radiotherapy in less than 6 months had a longer survival than patients who had more than 6 months (p <0.001). Therefore, patients with a delay of more than 6 months in the initial adjuvant radiotherapy treatment had an impact on the 5-year disease-free survival. Conclusion: This study is not conclusive, but we were able to observe data that show a worsening in the patient’s survival and prognosis in relation to the delay in the radiotherapy treatment. However, the waiting time for radiotherapy should be as short as reasonably possible, as there is a possibility that this delay will cause worse disease control rates.

5

Kyroudis, Christos A., Dimitra D. Dionysiou, Eleni A. Kolokotroni, Jesper F. Kallehague, Kari Tanderup, and Georgios S. Stamatakos. "Simulation of cervical cancer response to radiotherapy." In 2014 6th International Advanced Research Workshop on "In Silico Oncology and Cancer Investigation". IEEE, 2014. http://dx.doi.org/10.1109/iarwisoci.2014.7034637.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Leonard, CE, RD Sobus, S. Fryman, S. Sedlacek, J. Kercher, J. Widner, L. Asmar, et al. "Abstract P1-10-03: A randomized trial of accelerated breast radiotherapy utilizing either 3-dimensional radiotherapy versus intensity modulated radiotherapy." In Abstracts: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, Texas. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.sabcs16-p1-10-03.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Sousa, Paulo Roberto Moura de, Mauricio de Aquino Resende, Ailton Joioso, Raimundo Jovita Araujo Bonfim, and Carlos Eduardo Witoslawski Breda. "FAT GRAFTING AFTER RADIOTHERAPY AND BREAST IMPLANT." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2095.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

This is a case report of reconstruction of the right breast and aesthetic improvement of the left breast, in a 52-year-old smoker woman, with bilateral breast cancer, neoadjuvant chemotherapy, modified radical mastectomy on the right, quadrantectomy with left, lymphadenectomy, and radiotherapy (RT). She sought the Amaral Carvalho Hospital for reconstructive surgery after 6 years of treatment. She underwent fat grafting (FG) with 237 mL on the right breast and 90 mL on the left breast and correction of the left areola. After 6 months, a retromuscular tissue expander was placed on the right, and remodeling of the breast and correction of the surgical scar are done on the left. After 8 months of achieving expansion with 350 mL of saline solution, the tissue expander was replaced by a wide base anatomical prosthesis with 485 mL and a 225 mL nonanatomical round prosthesis additive to the left. RT makes breast reconstruction difficult, as it gives better results with myocutaneous flaps. FG has a regenerative effect on irradiated tissues. Historically, reconstruction with autologous tissue is preferable to reconstruction with implantation in patients irradiated after mastectomy, as it presents less reoperation (16.6% vs. 37.0%, p<0.0001), total complications (30.9% vs. 41.3%, p <0.0001), and reconstructive failure (1.6% vs. 16.8%, p<0.0001). Radiodermite affects more than 90% of patients treated with RT. The dermis is affected with an increase in fibrosis, reduction in the number of capillaries, and irregular distribution. FG is able to reverse these changes. FG improves the characteristics of irradiated tissue, restores elasticity, and allows breast reconstruction with an implant without a myocutaneous flap.

8

Letzkus, Jaime, María José del Río, Jorge Gamboa Galté, José Manuel Lagos Bononato, G. Alejandro Belmar, and Andrea Sepúlveda H. "PREPECTORAL BREAST RECONSTRUCTION: A PRELIMINARY REPORT OF A CHILEAN EXPERIENCE IN 46 PATIENTS." In Brazilian Breast Cancer Symposium 2022. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s2079.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Prepectoral total breast reconstruction (PPTBR) has become a popular technique due to the many benefits observed in properly selected patients. Compared with the retropectoral implant position, PPTBR has the advantage of maintaining the pectoral major muscle in its anatomic original position, avoiding acute and chronic pain, maintaining better extremity strength and motion, and avoiding animation deformity and post-radiotherapy pectoral fibrosis. The basic principles of the technique can be used with a tissue expander or permanent implants. We present the preliminary report of 46 patients (51 breasts). In all, 20 out of the 46 patients had an association with radiotherapy; 18 of them received post-mastectomy radiotherapy and 2 received total breast irradiation on previous conservative treatment. The period of follow-up was 2–32 months, beginning in July 2019. The main surgical approach was using a lateral aspect of the inframammary fold incision. Depending on the new subdermal implant pocket width, in 20 patients, a synthetic mesh was placed. We only had two major complications: one who required reintervention due to radionecrosis and conversion to a dorsal flap plus a permanent implant, and the other who required a change into a retropectoral plane reconstruction due to wound dehiscence. No implant infection of grade 3–4 capsular contraction has been reported so far. The aesthetic result was excellent for most patients and the surgeon’s opinion, according to the Harris scale.

9

Sebaaly, Anthony, Corinne Bassile, Tamara Akl, Georges Farha, Jad El Barouky, Fares Azoury, and Sandy Rihana. "Radiotherapy Treatment Planning System Simulation Lung Cancer Application." In 2018 IEEE International Multidisciplinary Conference on Engineering Technology (IMCET). IEEE, 2018. http://dx.doi.org/10.1109/imcet.2018.8603054.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Munteanu, Anca, Silvana Ojica, Diana Ancuta Cojocaru, Catalina Ursache, Alina Rogojanu, and Anamaria Constantin. "Breast cancer radiotherapy: Past, present and techniques evolving." In 2015 E-Health and Bioengineering Conference (EHB). IEEE, 2015. http://dx.doi.org/10.1109/ehb.2015.7391480.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Cancer Radiotherapy":

1

Buchsbaum, Donald J. Genetic Radiotherapy of Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, December 2003. http://dx.doi.org/10.21236/ada422767.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Li, Chuan-Yuan. Enhancement of Prostate Cancer Radiotherapy by Immunogenetherapy. Fort Belvoir, VA: Defense Technical Information Center, February 2004. http://dx.doi.org/10.21236/ada424647.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Silvia S. Jurisson, PhD. Rhodium-105 Bombesin Analogs for Prostate Cancer Radiotherapy. Office of Scientific and Technical Information (OSTI), December 2005. http://dx.doi.org/10.2172/951630.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Rogers, Buck E. Enhanced Peptide Radiotherapy of Prostate Cancer Using Targeted Adenoviral Vectors. Fort Belvoir, VA: Defense Technical Information Center, June 2004. http://dx.doi.org/10.21236/ada428235.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Chen, Lili. MR Imaging Based Treatment Planning for Radiotherapy of Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, February 2005. http://dx.doi.org/10.21236/ada435143.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Park, Jong Y. Genetic and Epigenetic Biomarkers for Recurrent Prostate Cancer After Radiotherapy. Fort Belvoir, VA: Defense Technical Information Center, May 2014. http://dx.doi.org/10.21236/ada609389.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Park, Jong. Genetic and Epigenetic Biomarkers for Recurrent Prostate Cancer After Radiotherapy. Fort Belvoir, VA: Defense Technical Information Center, May 2013. http://dx.doi.org/10.21236/ada581491.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Rogers, Buck E. Enhanced Peptide Radiotherapy of Prostate Cancer Using Targeted Adenoviral Vectors. Fort Belvoir, VA: Defense Technical Information Center, June 2003. http://dx.doi.org/10.21236/ada420846.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Chen, Lili. MR Imaging Based Treatment Planning for Radiotherapy of Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, February 2007. http://dx.doi.org/10.21236/ada468037.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Fenton, Bruce M. Potentiation of Prostate Cancer Radiotherapy Using Antiangiogenic and Antitumor Therapies. Fort Belvoir, VA: Defense Technical Information Center, October 2007. http://dx.doi.org/10.21236/ada478113.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.